https://www.seppalalab.org/author/toni-seppala/Toni SeppäläHugo Blox Builder (https://hugoblox.com)enThu, 01 Jan 2026 00:00:00 +0000https://www.seppalalab.org/author/toni-seppala/avatar_hu_68fc3b8986ef4d15.jpghttps://www.seppalalab.org/author/toni-seppala/https://www.seppalalab.org/project/predi-lynch/Thu, 01 Jan 2026 00:00:00 +0000https://www.seppalalab.org/project/predi-lynch/<p>The PREDI-LYNCH project is dedicated to advancing early detection and personalized prevention of Lynch syndrome, a hereditary condition that predisposes individuals to colorectal, endometrial, and several other types of cancer.</p> <p>Through collaboration with leading medical institutions and researchers, the project aims to refine risk assessment tools that combine genetic markers, family history, and lifestyle factors. This holistic approach enables healthcare providers to offer tailored screening and prevention strategies, ultimately reducing cancer incidence and improving long-term patient outcomes.</p> <p>PREDI-LYNCH also emphasizes patient education and accessibility, ensuring that risk prediction tools are user-friendly and available to diverse populations. By bridging the gap between research and clinical practice, the PREDI-LYNCH project strives to empower individuals and clinicians alike with actionable insights for precision medicine in hereditary cancer prevention.</p> <ul> <li><strong>Duration:</strong> 2025–2031</li> <li><strong>Role:</strong> Leader of clinical studies</li> </ul>https://www.seppalalab.org/project/syncope/Wed, 01 Sep 2021 00:00:00 +0000https://www.seppalalab.org/project/syncope/<p>The overall goal of the project is to test if early systemic control and precision-targeted selection to adjuvant chemotherapy, as a comprehensive treatment strategy, would reduce the rate of systemic recurrence in mrEMVI+ without increasing the harms from adverse effects. The specific research questions are:</p> <ol> <li>Is application of systemic control with precision approach over the course of the rectal cancer therapy logistically feasible?</li> <li>Does systemic control and precision approach as a treatment strategy improve recurrence-free survival of rectal cancer patients?.</li> <li>Is circulating tumor DNA a reliable postoperative biomarker of minimal residual disease (MRD) for adjuvant chemotherapy decisions?</li> <li>Does chemosensitivity of patient-derived organoids (PDO) correlates to therapy response in a prospective setting?</li> </ol> <ul> <li><strong>Duration:</strong> [Add duration]</li> <li><strong>Role:</strong> [Add role]</li> </ul>